Joseph Eid, M.D., assumed the role of Executive Vice President of Research & Development at Geron Corp. on November 11, 2024. Dr. Eid brings a wealth of experience in the biopharmaceutical industry, particularly in oncology and hematology. Prior to joining Geron, he served as the Chief Medical Officer at a leading biotech firm, where he was instrumental in advancing several novel cancer therapies from early-stage development through to successful regulatory approval. His strategic vision and deep understanding of clinical development have been pivotal in transforming innovative ideas into life-saving treatments. Throughout his career, Dr. Eid has been recognized for his contributions to medical research and development. He has authored numerous peer-reviewed articles and has been a frequent speaker at international conferences, sharing insights on the latest advancements in oncology. His work has been particularly influential in the field of immunotherapy, where he has led efforts to develop targeted therapies that enhance the body's immune response against cancer cells. Dr. Eid's commitment to advancing patient care is evident in his leadership style, which emphasizes collaboration and a patient-centric approach to drug development. At Geron Corp., Dr. Eid is tasked with overseeing the company's research and development pipeline, which focuses on telomerase inhibition and its potential applications in treating cancer and other diseases. His role involves steering the company's scientific strategy, managing clinical trials, and ensuring that Geron remains at the forefront of biotechnological innovation. With his extensive experience and proven track record, Dr. Eid is well-positioned to drive Geron's mission of developing groundbreaking therapies that address unmet medical needs.